We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Eli Lilly has published its revenue increased 9% to $6.4bn in the second quarter (Q2) of 2018, compared with $5.8bn in Q2 2017, due to a higher demand for new pharmaceutical products in the quarter.